S31: Bio-based Technology Commercialization: The role of lab to pilot scale-up

Tuesday, November 5, 2013: 3:00 PM
Islands Ballroom F-J (Marriott Marco Island)
Susanne Kleff and James Wynn, MBI International, Lansing, MI
Bio-based technologies have their inception and first demonstration at laboratory scale. Progression from laboratory to commercial scale has many hurdles, technical and financial, that can derail even the most promising technologies.

Technical difficulties during commercialization fall loosely into three interrelated categories (i) fermentation performance (ii) product purification and (iii) process scale-up.

Fermentation factors impacting process scale up include (i) seed train development, (ii) medium cost, (iii) process performance, (iii) scale dependent mass-transfer issues

Challenges during product purification include (i) recovery losses (ii) chemical purity and (iii) generating  product for application testing.

Although demonstration of a bio-based technology at pilot scale (>1000L) is a required stage in the progression from laboratory to commercial scale, building a pilot plant may not be a good investment for most companies and has proven insurmountable in many instances.

MBI specializes in helping industrial biotechnology companies overcome some of these hurdles and demonstrate their technologies at 3000 L pilot scale, a point sufficient to establish scalability and commercial potential of a technology and plays a key role in securing further investment.

Opportunities and challenges of scale-up will be discussed with emphasis on the added challenges in the use of non-food derived carbon feedstocks.